nodes	percent_of_prediction	percent_of_DWPC	metapath
Apraclonidine—ADRA1A—Phendimetrazine—obesity	0.112	0.153	CbGbCtD
Apraclonidine—ADRA2C—Methamphetamine—obesity	0.107	0.147	CbGbCtD
Apraclonidine—ADRA2B—Methamphetamine—obesity	0.102	0.139	CbGbCtD
Apraclonidine—ADRA2A—Benzphetamine—obesity	0.0887	0.121	CbGbCtD
Apraclonidine—ADRA1A—Benzphetamine—obesity	0.085	0.116	CbGbCtD
Apraclonidine—ADRA2A—Phenylpropanolamine—obesity	0.0846	0.116	CbGbCtD
Apraclonidine—ADRA1A—Phenylpropanolamine—obesity	0.0811	0.111	CbGbCtD
Apraclonidine—ADRA2A—Methamphetamine—obesity	0.0709	0.0969	CbGbCtD
Apraclonidine—Abdominal pain—Phentermine—obesity	0.000487	0.0033	CcSEcCtD
Apraclonidine—Insomnia—Diethylpropion—obesity	0.000485	0.00329	CcSEcCtD
Apraclonidine—Vasodilation procedure—Topiramate—obesity	0.000483	0.00327	CcSEcCtD
Apraclonidine—Vasodilation—Topiramate—obesity	0.000483	0.00327	CcSEcCtD
Apraclonidine—Disturbance in sexual arousal—Bupropion—obesity	0.000479	0.00325	CcSEcCtD
Apraclonidine—Asthma—Sibutramine—obesity	0.000479	0.00325	CcSEcCtD
Apraclonidine—Dyspnoea—Diethylpropion—obesity	0.000478	0.00324	CcSEcCtD
Apraclonidine—Somnolence—Diethylpropion—obesity	0.000476	0.00323	CcSEcCtD
Apraclonidine—Abdominal discomfort—Orlistat—obesity	0.000475	0.00322	CcSEcCtD
Apraclonidine—Hypersensitivity—Phenylpropanolamine—obesity	0.000474	0.00322	CcSEcCtD
Apraclonidine—Headache—Phendimetrazine—obesity	0.000472	0.0032	CcSEcCtD
Apraclonidine—Face oedema—Bupropion—obesity	0.000467	0.00316	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Cimetidine—obesity	0.000465	0.00315	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Diethylpropion—obesity	0.000463	0.00314	CcSEcCtD
Apraclonidine—Irritability—Bupropion—obesity	0.000461	0.00313	CcSEcCtD
Apraclonidine—Lacrimation increased—Topiramate—obesity	0.00046	0.00312	CcSEcCtD
Apraclonidine—Constipation—Diethylpropion—obesity	0.000458	0.00311	CcSEcCtD
Apraclonidine—Somnolence—Cimetidine—obesity	0.000453	0.00307	CcSEcCtD
Apraclonidine—Nausea—Phendimetrazine—obesity	0.000448	0.00303	CcSEcCtD
Apraclonidine—Asthenia—Phentermine—obesity	0.000442	0.003	CcSEcCtD
Apraclonidine—Feeling abnormal—Diethylpropion—obesity	0.000442	0.00299	CcSEcCtD
Apraclonidine—Infestation—Orlistat—obesity	0.000441	0.00299	CcSEcCtD
Apraclonidine—Infestation NOS—Orlistat—obesity	0.000441	0.00299	CcSEcCtD
Apraclonidine—Fatigue—Cimetidine—obesity	0.00044	0.00298	CcSEcCtD
Apraclonidine—Constipation—Cimetidine—obesity	0.000436	0.00296	CcSEcCtD
Apraclonidine—Nasopharyngitis—Bupropion—obesity	0.000432	0.00293	CcSEcCtD
Apraclonidine—Coordination abnormal—Topiramate—obesity	0.000432	0.00293	CcSEcCtD
Apraclonidine—Dizziness—Phenylpropanolamine—obesity	0.000426	0.00289	CcSEcCtD
Apraclonidine—Diarrhoea—Phentermine—obesity	0.000421	0.00286	CcSEcCtD
Apraclonidine—Feeling abnormal—Cimetidine—obesity	0.00042	0.00285	CcSEcCtD
Apraclonidine—Asthma—Bupropion—obesity	0.000418	0.00283	CcSEcCtD
Apraclonidine—Conjunctivitis—Sibutramine—obesity	0.000415	0.00281	CcSEcCtD
Apraclonidine—Clonidine—SLC22A1—obesity	0.000409	1	CrCbGaD
Apraclonidine—Vomiting—Phenylpropanolamine—obesity	0.000409	0.00277	CcSEcCtD
Apraclonidine—Dizziness—Phentermine—obesity	0.000407	0.00276	CcSEcCtD
Apraclonidine—Dermatitis—Phenylpropanolamine—obesity	0.000406	0.00275	CcSEcCtD
Apraclonidine—Abdominal discomfort—Bupropion—obesity	0.0004	0.00271	CcSEcCtD
Apraclonidine—Photophobia—Topiramate—obesity	0.000398	0.0027	CcSEcCtD
Apraclonidine—Haemorrhage—Orlistat—obesity	0.000396	0.00269	CcSEcCtD
Apraclonidine—Pharyngitis—Orlistat—obesity	0.000393	0.00267	CcSEcCtD
Apraclonidine—Dry eye—Topiramate—obesity	0.000392	0.00266	CcSEcCtD
Apraclonidine—Vomiting—Phentermine—obesity	0.000392	0.00266	CcSEcCtD
Apraclonidine—Bradycardia—Sibutramine—obesity	0.00039	0.00265	CcSEcCtD
Apraclonidine—Oedema peripheral—Orlistat—obesity	0.00039	0.00265	CcSEcCtD
Apraclonidine—Dermatitis—Phentermine—obesity	0.000388	0.00263	CcSEcCtD
Apraclonidine—Headache—Phentermine—obesity	0.000386	0.00262	CcSEcCtD
Apraclonidine—Rhinitis—Sibutramine—obesity	0.000384	0.00261	CcSEcCtD
Apraclonidine—Haemorrhage—Sibutramine—obesity	0.000383	0.0026	CcSEcCtD
Apraclonidine—Nausea—Phenylpropanolamine—obesity	0.000382	0.00259	CcSEcCtD
Apraclonidine—Pharyngitis—Sibutramine—obesity	0.000381	0.00258	CcSEcCtD
Apraclonidine—Oedema peripheral—Sibutramine—obesity	0.000378	0.00256	CcSEcCtD
Apraclonidine—Hypersensitivity—Cimetidine—obesity	0.000376	0.00255	CcSEcCtD
Apraclonidine—Infestation NOS—Bupropion—obesity	0.000372	0.00252	CcSEcCtD
Apraclonidine—Infestation—Bupropion—obesity	0.000372	0.00252	CcSEcCtD
Apraclonidine—Abnormal vision—Topiramate—obesity	0.00037	0.00251	CcSEcCtD
Apraclonidine—Visual impairment—Sibutramine—obesity	0.00037	0.00251	CcSEcCtD
Apraclonidine—Diarrhoea—Diethylpropion—obesity	0.000367	0.00249	CcSEcCtD
Apraclonidine—Nausea—Phentermine—obesity	0.000366	0.00248	CcSEcCtD
Apraclonidine—Asthenia—Cimetidine—obesity	0.000366	0.00248	CcSEcCtD
Apraclonidine—Conjunctivitis—Bupropion—obesity	0.000362	0.00245	CcSEcCtD
Apraclonidine—Eye disorder—Sibutramine—obesity	0.000358	0.00243	CcSEcCtD
Apraclonidine—Mediastinal disorder—Orlistat—obesity	0.000357	0.00242	CcSEcCtD
Apraclonidine—Dizziness—Diethylpropion—obesity	0.000354	0.0024	CcSEcCtD
Apraclonidine—Diarrhoea—Cimetidine—obesity	0.000349	0.00237	CcSEcCtD
Apraclonidine—Angiopathy—Sibutramine—obesity	0.000348	0.00236	CcSEcCtD
Apraclonidine—Mental disorder—Orlistat—obesity	0.000347	0.00235	CcSEcCtD
Apraclonidine—Arrhythmia—Sibutramine—obesity	0.000343	0.00232	CcSEcCtD
Apraclonidine—Eye pain—Topiramate—obesity	0.000341	0.00231	CcSEcCtD
Apraclonidine—Vomiting—Diethylpropion—obesity	0.000341	0.00231	CcSEcCtD
Apraclonidine—Dysgeusia—Orlistat—obesity	0.000338	0.00229	CcSEcCtD
Apraclonidine—Dermatitis—Diethylpropion—obesity	0.000338	0.00229	CcSEcCtD
Apraclonidine—Dizziness—Cimetidine—obesity	0.000337	0.00229	CcSEcCtD
Apraclonidine—Headache—Diethylpropion—obesity	0.000336	0.00228	CcSEcCtD
Apraclonidine—Rhinitis—Bupropion—obesity	0.000335	0.00227	CcSEcCtD
Apraclonidine—Haemorrhage—Bupropion—obesity	0.000334	0.00227	CcSEcCtD
Apraclonidine—Libido decreased—Topiramate—obesity	0.000332	0.00225	CcSEcCtD
Apraclonidine—Pharyngitis—Bupropion—obesity	0.000332	0.00225	CcSEcCtD
Apraclonidine—Oedema peripheral—Bupropion—obesity	0.000329	0.00223	CcSEcCtD
Apraclonidine—Tension—Sibutramine—obesity	0.000328	0.00222	CcSEcCtD
Apraclonidine—Dysgeusia—Sibutramine—obesity	0.000327	0.00222	CcSEcCtD
Apraclonidine—Vision blurred—Orlistat—obesity	0.000325	0.0022	CcSEcCtD
Apraclonidine—Nervousness—Sibutramine—obesity	0.000324	0.0022	CcSEcCtD
Apraclonidine—Vomiting—Cimetidine—obesity	0.000324	0.0022	CcSEcCtD
Apraclonidine—Visual impairment—Bupropion—obesity	0.000322	0.00218	CcSEcCtD
Apraclonidine—Dermatitis—Cimetidine—obesity	0.000321	0.00218	CcSEcCtD
Apraclonidine—Ill-defined disorder—Orlistat—obesity	0.00032	0.00217	CcSEcCtD
Apraclonidine—Headache—Cimetidine—obesity	0.000319	0.00217	CcSEcCtD
Apraclonidine—Nausea—Diethylpropion—obesity	0.000318	0.00216	CcSEcCtD
Apraclonidine—Vision blurred—Sibutramine—obesity	0.000315	0.00213	CcSEcCtD
Apraclonidine—Eye disorder—Bupropion—obesity	0.000312	0.00212	CcSEcCtD
Apraclonidine—Malaise—Orlistat—obesity	0.000311	0.00211	CcSEcCtD
Apraclonidine—Ill-defined disorder—Sibutramine—obesity	0.00031	0.0021	CcSEcCtD
Apraclonidine—Disturbance in sexual arousal—Topiramate—obesity	0.000305	0.00207	CcSEcCtD
Apraclonidine—Palpitations—Orlistat—obesity	0.000305	0.00207	CcSEcCtD
Apraclonidine—Angiopathy—Bupropion—obesity	0.000303	0.00206	CcSEcCtD
Apraclonidine—Nausea—Cimetidine—obesity	0.000303	0.00205	CcSEcCtD
Apraclonidine—Mediastinal disorder—Bupropion—obesity	0.000301	0.00204	CcSEcCtD
Apraclonidine—Malaise—Sibutramine—obesity	0.000301	0.00204	CcSEcCtD
Apraclonidine—Syncope—Sibutramine—obesity	0.000299	0.00203	CcSEcCtD
Apraclonidine—Arrhythmia—Bupropion—obesity	0.000299	0.00202	CcSEcCtD
Apraclonidine—Face oedema—Topiramate—obesity	0.000297	0.00201	CcSEcCtD
Apraclonidine—Palpitations—Sibutramine—obesity	0.000295	0.002	CcSEcCtD
Apraclonidine—Irritability—Topiramate—obesity	0.000294	0.00199	CcSEcCtD
Apraclonidine—Myalgia—Orlistat—obesity	0.000294	0.00199	CcSEcCtD
Apraclonidine—Chest pain—Orlistat—obesity	0.000294	0.00199	CcSEcCtD
Apraclonidine—Mental disorder—Bupropion—obesity	0.000293	0.00199	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Orlistat—obesity	0.000292	0.00198	CcSEcCtD
Apraclonidine—Discomfort—Orlistat—obesity	0.00029	0.00197	CcSEcCtD
Apraclonidine—Dry mouth—Orlistat—obesity	0.000287	0.00195	CcSEcCtD
Apraclonidine—Tension—Bupropion—obesity	0.000286	0.00194	CcSEcCtD
Apraclonidine—Dysgeusia—Bupropion—obesity	0.000285	0.00193	CcSEcCtD
Apraclonidine—Chest pain—Sibutramine—obesity	0.000284	0.00193	CcSEcCtD
Apraclonidine—Myalgia—Sibutramine—obesity	0.000284	0.00193	CcSEcCtD
Apraclonidine—Nervousness—Bupropion—obesity	0.000283	0.00192	CcSEcCtD
Apraclonidine—Oedema—Orlistat—obesity	0.000282	0.00191	CcSEcCtD
Apraclonidine—Discomfort—Sibutramine—obesity	0.000281	0.0019	CcSEcCtD
Apraclonidine—Infection—Orlistat—obesity	0.00028	0.0019	CcSEcCtD
Apraclonidine—Dry mouth—Sibutramine—obesity	0.000278	0.00188	CcSEcCtD
Apraclonidine—Nervous system disorder—Orlistat—obesity	0.000276	0.00187	CcSEcCtD
Apraclonidine—Nasopharyngitis—Topiramate—obesity	0.000275	0.00187	CcSEcCtD
Apraclonidine—Vision blurred—Bupropion—obesity	0.000274	0.00186	CcSEcCtD
Apraclonidine—Skin disorder—Orlistat—obesity	0.000273	0.00185	CcSEcCtD
Apraclonidine—Oedema—Sibutramine—obesity	0.000272	0.00185	CcSEcCtD
Apraclonidine—Infection—Sibutramine—obesity	0.000271	0.00183	CcSEcCtD
Apraclonidine—Ill-defined disorder—Bupropion—obesity	0.00027	0.00183	CcSEcCtD
Apraclonidine—Asthma—Topiramate—obesity	0.000266	0.0018	CcSEcCtD
Apraclonidine—Skin disorder—Sibutramine—obesity	0.000265	0.00179	CcSEcCtD
Apraclonidine—Malaise—Bupropion—obesity	0.000262	0.00178	CcSEcCtD
Apraclonidine—Syncope—Bupropion—obesity	0.000261	0.00177	CcSEcCtD
Apraclonidine—Palpitations—Bupropion—obesity	0.000257	0.00174	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Orlistat—obesity	0.000256	0.00174	CcSEcCtD
Apraclonidine—Abdominal discomfort—Topiramate—obesity	0.000255	0.00173	CcSEcCtD
Apraclonidine—Insomnia—Orlistat—obesity	0.000255	0.00173	CcSEcCtD
Apraclonidine—Paraesthesia—Orlistat—obesity	0.000253	0.00171	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Sibutramine—obesity	0.000248	0.00168	CcSEcCtD
Apraclonidine—Myalgia—Bupropion—obesity	0.000248	0.00168	CcSEcCtD
Apraclonidine—Chest pain—Bupropion—obesity	0.000248	0.00168	CcSEcCtD
Apraclonidine—Insomnia—Sibutramine—obesity	0.000246	0.00167	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Bupropion—obesity	0.000246	0.00167	CcSEcCtD
Apraclonidine—Discomfort—Bupropion—obesity	0.000245	0.00166	CcSEcCtD
Apraclonidine—Paraesthesia—Sibutramine—obesity	0.000245	0.00166	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Orlistat—obesity	0.000243	0.00165	CcSEcCtD
Apraclonidine—Dyspnoea—Sibutramine—obesity	0.000243	0.00165	CcSEcCtD
Apraclonidine—Fatigue—Orlistat—obesity	0.000243	0.00165	CcSEcCtD
Apraclonidine—Dry mouth—Bupropion—obesity	0.000242	0.00164	CcSEcCtD
Apraclonidine—Somnolence—Sibutramine—obesity	0.000242	0.00164	CcSEcCtD
Apraclonidine—Pain—Orlistat—obesity	0.000241	0.00163	CcSEcCtD
Apraclonidine—Oedema—Bupropion—obesity	0.000238	0.00161	CcSEcCtD
Apraclonidine—Infestation NOS—Topiramate—obesity	0.000237	0.00161	CcSEcCtD
Apraclonidine—Infestation—Topiramate—obesity	0.000237	0.00161	CcSEcCtD
Apraclonidine—Infection—Bupropion—obesity	0.000236	0.0016	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Sibutramine—obesity	0.000235	0.00159	CcSEcCtD
Apraclonidine—Pain—Sibutramine—obesity	0.000233	0.00158	CcSEcCtD
Apraclonidine—Constipation—Sibutramine—obesity	0.000233	0.00158	CcSEcCtD
Apraclonidine—Nervous system disorder—Bupropion—obesity	0.000233	0.00158	CcSEcCtD
Apraclonidine—Feeling abnormal—Orlistat—obesity	0.000232	0.00157	CcSEcCtD
Apraclonidine—Skin disorder—Bupropion—obesity	0.000231	0.00156	CcSEcCtD
Apraclonidine—Conjunctivitis—Topiramate—obesity	0.000231	0.00156	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Orlistat—obesity	0.00023	0.00156	CcSEcCtD
Apraclonidine—Feeling abnormal—Sibutramine—obesity	0.000225	0.00152	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Sibutramine—obesity	0.000223	0.00151	CcSEcCtD
Apraclonidine—Abdominal pain—Orlistat—obesity	0.000223	0.00151	CcSEcCtD
Apraclonidine—Bradycardia—Topiramate—obesity	0.000217	0.00147	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Bupropion—obesity	0.000216	0.00147	CcSEcCtD
Apraclonidine—Abdominal pain—Sibutramine—obesity	0.000215	0.00146	CcSEcCtD
Apraclonidine—Insomnia—Bupropion—obesity	0.000215	0.00146	CcSEcCtD
Apraclonidine—Rhinitis—Topiramate—obesity	0.000214	0.00145	CcSEcCtD
Apraclonidine—Paraesthesia—Bupropion—obesity	0.000213	0.00145	CcSEcCtD
Apraclonidine—Haemorrhage—Topiramate—obesity	0.000213	0.00144	CcSEcCtD
Apraclonidine—Dyspnoea—Bupropion—obesity	0.000212	0.00144	CcSEcCtD
Apraclonidine—Pharyngitis—Topiramate—obesity	0.000211	0.00143	CcSEcCtD
Apraclonidine—Somnolence—Bupropion—obesity	0.000211	0.00143	CcSEcCtD
Apraclonidine—Oedema peripheral—Topiramate—obesity	0.00021	0.00142	CcSEcCtD
Apraclonidine—Hypersensitivity—Orlistat—obesity	0.000207	0.00141	CcSEcCtD
Apraclonidine—Visual impairment—Topiramate—obesity	0.000205	0.00139	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Bupropion—obesity	0.000205	0.00139	CcSEcCtD
Apraclonidine—Fatigue—Bupropion—obesity	0.000205	0.00139	CcSEcCtD
Apraclonidine—Pain—Bupropion—obesity	0.000203	0.00138	CcSEcCtD
Apraclonidine—Constipation—Bupropion—obesity	0.000203	0.00138	CcSEcCtD
Apraclonidine—Asthenia—Orlistat—obesity	0.000202	0.00137	CcSEcCtD
Apraclonidine—Hypersensitivity—Sibutramine—obesity	0.000201	0.00136	CcSEcCtD
Apraclonidine—Pruritus—Orlistat—obesity	0.000199	0.00135	CcSEcCtD
Apraclonidine—Eye disorder—Topiramate—obesity	0.000199	0.00135	CcSEcCtD
Apraclonidine—Feeling abnormal—Bupropion—obesity	0.000196	0.00133	CcSEcCtD
Apraclonidine—Asthenia—Sibutramine—obesity	0.000195	0.00133	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Bupropion—obesity	0.000194	0.00132	CcSEcCtD
Apraclonidine—Angiopathy—Topiramate—obesity	0.000193	0.00131	CcSEcCtD
Apraclonidine—Pruritus—Sibutramine—obesity	0.000193	0.00131	CcSEcCtD
Apraclonidine—Diarrhoea—Orlistat—obesity	0.000193	0.00131	CcSEcCtD
Apraclonidine—Mediastinal disorder—Topiramate—obesity	0.000192	0.0013	CcSEcCtD
Apraclonidine—Abdominal pain—Bupropion—obesity	0.000188	0.00127	CcSEcCtD
Apraclonidine—Mental disorder—Topiramate—obesity	0.000187	0.00126	CcSEcCtD
Apraclonidine—Diarrhoea—Sibutramine—obesity	0.000186	0.00126	CcSEcCtD
Apraclonidine—Dizziness—Orlistat—obesity	0.000186	0.00126	CcSEcCtD
Apraclonidine—Erythema—Topiramate—obesity	0.000185	0.00126	CcSEcCtD
Apraclonidine—Tension—Topiramate—obesity	0.000182	0.00123	CcSEcCtD
Apraclonidine—Dysgeusia—Topiramate—obesity	0.000182	0.00123	CcSEcCtD
Apraclonidine—Dizziness—Sibutramine—obesity	0.00018	0.00122	CcSEcCtD
Apraclonidine—Nervousness—Topiramate—obesity	0.00018	0.00122	CcSEcCtD
Apraclonidine—Vomiting—Orlistat—obesity	0.000179	0.00121	CcSEcCtD
Apraclonidine—Dermatitis—Orlistat—obesity	0.000177	0.0012	CcSEcCtD
Apraclonidine—Headache—Orlistat—obesity	0.000176	0.0012	CcSEcCtD
Apraclonidine—Hypersensitivity—Bupropion—obesity	0.000175	0.00119	CcSEcCtD
Apraclonidine—Vision blurred—Topiramate—obesity	0.000175	0.00118	CcSEcCtD
Apraclonidine—Vomiting—Sibutramine—obesity	0.000173	0.00117	CcSEcCtD
Apraclonidine—Ill-defined disorder—Topiramate—obesity	0.000172	0.00117	CcSEcCtD
Apraclonidine—Dermatitis—Sibutramine—obesity	0.000172	0.00116	CcSEcCtD
Apraclonidine—Headache—Sibutramine—obesity	0.000171	0.00116	CcSEcCtD
Apraclonidine—Asthenia—Bupropion—obesity	0.00017	0.00116	CcSEcCtD
Apraclonidine—Pruritus—Bupropion—obesity	0.000168	0.00114	CcSEcCtD
Apraclonidine—Nausea—Orlistat—obesity	0.000167	0.00113	CcSEcCtD
Apraclonidine—Malaise—Topiramate—obesity	0.000167	0.00113	CcSEcCtD
Apraclonidine—Syncope—Topiramate—obesity	0.000166	0.00113	CcSEcCtD
Apraclonidine—Palpitations—Topiramate—obesity	0.000164	0.00111	CcSEcCtD
Apraclonidine—Diarrhoea—Bupropion—obesity	0.000163	0.0011	CcSEcCtD
Apraclonidine—Nausea—Sibutramine—obesity	0.000162	0.0011	CcSEcCtD
Apraclonidine—Myalgia—Topiramate—obesity	0.000158	0.00107	CcSEcCtD
Apraclonidine—Chest pain—Topiramate—obesity	0.000158	0.00107	CcSEcCtD
Apraclonidine—Dizziness—Bupropion—obesity	0.000157	0.00106	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Topiramate—obesity	0.000157	0.00106	CcSEcCtD
Apraclonidine—Discomfort—Topiramate—obesity	0.000156	0.00106	CcSEcCtD
Apraclonidine—Dry mouth—Topiramate—obesity	0.000154	0.00105	CcSEcCtD
Apraclonidine—Oedema—Topiramate—obesity	0.000151	0.00103	CcSEcCtD
Apraclonidine—Vomiting—Bupropion—obesity	0.000151	0.00102	CcSEcCtD
Apraclonidine—Infection—Topiramate—obesity	0.00015	0.00102	CcSEcCtD
Apraclonidine—Dermatitis—Bupropion—obesity	0.00015	0.00101	CcSEcCtD
Apraclonidine—Headache—Bupropion—obesity	0.000149	0.00101	CcSEcCtD
Apraclonidine—Nervous system disorder—Topiramate—obesity	0.000148	0.00101	CcSEcCtD
Apraclonidine—Skin disorder—Topiramate—obesity	0.000147	0.000996	CcSEcCtD
Apraclonidine—Nausea—Bupropion—obesity	0.000141	0.000956	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Topiramate—obesity	0.000138	0.000935	CcSEcCtD
Apraclonidine—Insomnia—Topiramate—obesity	0.000137	0.000928	CcSEcCtD
Apraclonidine—Paraesthesia—Topiramate—obesity	0.000136	0.000921	CcSEcCtD
Apraclonidine—Dyspnoea—Topiramate—obesity	0.000135	0.000915	CcSEcCtD
Apraclonidine—Somnolence—Topiramate—obesity	0.000135	0.000912	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Topiramate—obesity	0.000131	0.000886	CcSEcCtD
Apraclonidine—Fatigue—Topiramate—obesity	0.00013	0.000884	CcSEcCtD
Apraclonidine—Pain—Topiramate—obesity	0.000129	0.000877	CcSEcCtD
Apraclonidine—Constipation—Topiramate—obesity	0.000129	0.000877	CcSEcCtD
Apraclonidine—Feeling abnormal—Topiramate—obesity	0.000125	0.000845	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Topiramate—obesity	0.000124	0.000839	CcSEcCtD
Apraclonidine—Abdominal pain—Topiramate—obesity	0.00012	0.000811	CcSEcCtD
Apraclonidine—Hypersensitivity—Topiramate—obesity	0.000111	0.000756	CcSEcCtD
Apraclonidine—Asthenia—Topiramate—obesity	0.000109	0.000736	CcSEcCtD
Apraclonidine—Pruritus—Topiramate—obesity	0.000107	0.000726	CcSEcCtD
Apraclonidine—Diarrhoea—Topiramate—obesity	0.000104	0.000702	CcSEcCtD
Apraclonidine—Dizziness—Topiramate—obesity	0.0001	0.000678	CcSEcCtD
Apraclonidine—Vomiting—Topiramate—obesity	9.62e-05	0.000652	CcSEcCtD
Apraclonidine—Dermatitis—Topiramate—obesity	9.53e-05	0.000646	CcSEcCtD
Apraclonidine—Headache—Topiramate—obesity	9.48e-05	0.000643	CcSEcCtD
Apraclonidine—Nausea—Topiramate—obesity	8.99e-05	0.000609	CcSEcCtD
Apraclonidine—ADRA2C—Signaling Pathways—LPL—obesity	8.42e-06	7e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—TGFB1—obesity	8.37e-06	6.96e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—CAV1—obesity	8.36e-06	6.95e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—SOCS1—obesity	8.36e-06	6.95e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—FOXO1—obesity	8.36e-06	6.94e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—RPS6KB1—obesity	8.34e-06	6.93e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—APOA1—obesity	8.34e-06	6.93e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—POMC—obesity	8.33e-06	6.93e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PRL—obesity	8.31e-06	6.91e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PRKCD—obesity	8.3e-06	6.9e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—PIK3CD—obesity	8.28e-06	6.88e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—PIK3CB—obesity	8.26e-06	6.86e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—SOCS3—obesity	8.26e-06	6.86e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—STK11—obesity	8.19e-06	6.81e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—LPL—obesity	8.18e-06	6.8e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—CCL2—obesity	8.15e-06	6.78e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—HTR2A—obesity	8.12e-06	6.75e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—C3—obesity	8.11e-06	6.74e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PLG—obesity	8.1e-06	6.73e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—RHOA—obesity	8.09e-06	6.72e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—GNB3—obesity	8.08e-06	6.72e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—AKT2—obesity	8.01e-06	6.66e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—PIK3R1—obesity	8e-06	6.65e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—GPX1—obesity	7.98e-06	6.63e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—TYK2—obesity	7.97e-06	6.62e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—PIK3CB—obesity	7.95e-06	6.61e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—IGF2—obesity	7.94e-06	6.6e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—FOXO3—obesity	7.91e-06	6.57e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—RHOA—obesity	7.9e-06	6.57e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—ADRB2—obesity	7.89e-06	6.55e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—GNAS—obesity	7.87e-06	6.54e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—PIK3R1—obesity	7.82e-06	6.5e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—CD36—obesity	7.77e-06	6.46e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—SOCS1—obesity	7.77e-06	6.45e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PRKCD—obesity	7.75e-06	6.44e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—IRS2—obesity	7.72e-06	6.41e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—AGT—obesity	7.71e-06	6.41e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—APOB—obesity	7.71e-06	6.4e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—PIK3CD—obesity	7.7e-06	6.4e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—AKT1—obesity	7.67e-06	6.38e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—SOCS3—obesity	7.67e-06	6.37e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—PIK3CG—obesity	7.61e-06	6.33e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—HTR2A—obesity	7.59e-06	6.31e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—C3—obesity	7.58e-06	6.3e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—LEP—obesity	7.55e-06	6.28e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—APOE—obesity	7.55e-06	6.28e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CCL5—obesity	7.53e-06	6.25e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—GNB3—obesity	7.51e-06	6.24e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CAV1—obesity	7.48e-06	6.22e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—APOA1—obesity	7.47e-06	6.21e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—TYK2—obesity	7.4e-06	6.15e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—PIK3CB—obesity	7.39e-06	6.14e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—IGF2—obesity	7.38e-06	6.13e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—MTHFR—obesity	7.36e-06	6.12e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—LPL—obesity	7.36e-06	6.12e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—PPARG—obesity	7.35e-06	6.11e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—RHOA—obesity	7.34e-06	6.1e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—GNAS—obesity	7.31e-06	6.08e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—FOXO1—obesity	7.31e-06	6.07e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—RPS6KB1—obesity	7.29e-06	6.06e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—PIK3R1—obesity	7.27e-06	6.04e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—POMC—obesity	7.25e-06	6.02e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PPARA—obesity	7.22e-06	6e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—PIK3CB—obesity	7.22e-06	6e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—ESR1—obesity	7.21e-06	5.99e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—IRS2—obesity	7.21e-06	5.99e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—INS—obesity	7.21e-06	5.99e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—AGT—obesity	7.2e-06	5.98e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—AKT1—obesity	7.17e-06	5.96e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—APOB—obesity	7.16e-06	5.95e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—PIK3CA—obesity	7.13e-06	5.92e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—F2—obesity	7.12e-06	5.92e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PRKCB—obesity	7.12e-06	5.92e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—LEP—obesity	7.06e-06	5.86e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—APOE—obesity	7.06e-06	5.86e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—BAD—obesity	7.04e-06	5.85e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—AGT—obesity	6.99e-06	5.81e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CCL5—obesity	6.99e-06	5.81e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CAV1—obesity	6.99e-06	5.81e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—APOA1—obesity	6.97e-06	5.8e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—APOE—obesity	6.85e-06	5.7e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—LPL—obesity	6.84e-06	5.68e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PIK3CG—obesity	6.82e-06	5.67e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—CAV1—obesity	6.79e-06	5.64e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—FOXO1—obesity	6.79e-06	5.64e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PRKCD—obesity	6.78e-06	5.63e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—RPS6KB1—obesity	6.78e-06	5.63e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—APOA1—obesity	6.77e-06	5.63e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—IRS1—obesity	6.74e-06	5.6e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—ESR1—obesity	6.74e-06	5.6e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—PIK3CB—obesity	6.71e-06	5.58e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—PIK3CD—obesity	6.69e-06	5.56e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PRKCB—obesity	6.65e-06	5.53e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—F2—obesity	6.65e-06	5.53e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—HTR2A—obesity	6.63e-06	5.51e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—C3—obesity	6.63e-06	5.51e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—ALB—obesity	6.61e-06	5.49e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—BAD—obesity	6.57e-06	5.46e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—POMC—obesity	6.49e-06	5.39e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—INS—obesity	6.45e-06	5.36e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PIK3CG—obesity	6.37e-06	5.29e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CCL2—obesity	6.35e-06	5.28e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—NOS3—obesity	6.32e-06	5.25e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—PIK3R1—obesity	6.32e-06	5.25e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—IRS2—obesity	6.3e-06	5.24e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PRKCD—obesity	6.3e-06	5.23e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—AGT—obesity	6.29e-06	5.23e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—IRS1—obesity	6.29e-06	5.23e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—IGF1—obesity	6.24e-06	5.19e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—AKT2—obesity	6.24e-06	5.18e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PIK3CG—obesity	6.19e-06	5.14e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—LEP—obesity	6.17e-06	5.13e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—APOE—obesity	6.17e-06	5.13e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—HTR2A—obesity	6.16e-06	5.12e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—C3—obesity	6.16e-06	5.12e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CAV1—obesity	6.11e-06	5.08e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—APOA1—obesity	6.1e-06	5.07e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—POMC—obesity	6.06e-06	5.04e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—INS—obesity	6.03e-06	5.01e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PIK3CD—obesity	5.99e-06	4.98e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PPARG—obesity	5.97e-06	4.96e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—PIK3CA—obesity	5.94e-06	4.93e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CCL2—obesity	5.93e-06	4.93e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—SERPINE1—obesity	5.93e-06	4.93e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—ESR1—obesity	5.89e-06	4.89e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—POMC—obesity	5.89e-06	4.89e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—IRS2—obesity	5.86e-06	4.87e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—INS—obesity	5.85e-06	4.87e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—AGT—obesity	5.85e-06	4.86e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—PIK3CB—obesity	5.83e-06	4.85e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—IGF1—obesity	5.83e-06	4.85e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—AKT2—obesity	5.83e-06	4.84e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—AKT1—obesity	5.82e-06	4.84e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—F2—obesity	5.82e-06	4.83e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PRKCB—obesity	5.82e-06	4.83e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—PTGS2—obesity	5.78e-06	4.8e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—TYK2—obesity	5.76e-06	4.79e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—BAD—obesity	5.75e-06	4.78e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—LEP—obesity	5.73e-06	4.76e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—APOE—obesity	5.73e-06	4.76e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—RHOA—obesity	5.72e-06	4.75e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CAV1—obesity	5.68e-06	4.72e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—APOA1—obesity	5.66e-06	4.71e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—NOS3—obesity	5.66e-06	4.7e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PIK3R1—obesity	5.66e-06	4.7e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PIK3CD—obesity	5.6e-06	4.65e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PIK3CG—obesity	5.57e-06	4.63e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—PIK3CA—obesity	5.54e-06	4.61e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—SERPINE1—obesity	5.54e-06	4.6e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—IRS1—obesity	5.5e-06	4.57e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—ESR1—obesity	5.47e-06	4.55e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PIK3CD—obesity	5.44e-06	4.52e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PRKCB—obesity	5.4e-06	4.49e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—F2—obesity	5.4e-06	4.49e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—PIK3CA—obesity	5.39e-06	4.48e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—TYK2—obesity	5.38e-06	4.48e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—ALB—obesity	5.37e-06	4.46e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—RHOA—obesity	5.34e-06	4.44e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—BAD—obesity	5.34e-06	4.44e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—POMC—obesity	5.3e-06	4.4e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—NOS3—obesity	5.29e-06	4.39e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PIK3R1—obesity	5.29e-06	4.39e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—INS—obesity	5.27e-06	4.38e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PIK3CB—obesity	5.22e-06	4.34e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—MTOR—obesity	5.22e-06	4.34e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CCL2—obesity	5.18e-06	4.31e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PIK3CG—obesity	5.17e-06	4.3e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PIK3R1—obesity	5.13e-06	4.27e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—NOS3—obesity	5.13e-06	4.27e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—IRS1—obesity	5.11e-06	4.25e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—IGF1—obesity	5.1e-06	4.24e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—AKT2—obesity	5.09e-06	4.23e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—PIK3CA—obesity	5.03e-06	4.18e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—POMC—obesity	4.92e-06	4.09e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—INS—obesity	4.9e-06	4.07e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PIK3CD—obesity	4.89e-06	4.07e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—MTOR—obesity	4.88e-06	4.05e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PIK3CB—obesity	4.88e-06	4.05e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—AKT1—obesity	4.85e-06	4.03e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—PIK3CA—obesity	4.85e-06	4.03e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—SERPINE1—obesity	4.84e-06	4.02e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CCL2—obesity	4.82e-06	4e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—IL6—obesity	4.77e-06	3.97e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PIK3CB—obesity	4.74e-06	3.94e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—IGF1—obesity	4.74e-06	3.94e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—AKT2—obesity	4.73e-06	3.93e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—TYK2—obesity	4.71e-06	3.91e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PTGS2—obesity	4.7e-06	3.9e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—RHOA—obesity	4.67e-06	3.88e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—NOS3—obesity	4.62e-06	3.84e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PIK3R1—obesity	4.62e-06	3.84e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PIK3CD—obesity	4.55e-06	3.78e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—MMP9—obesity	4.54e-06	3.77e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—AKT1—obesity	4.53e-06	3.76e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—PIK3CA—obesity	4.5e-06	3.74e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—SERPINE1—obesity	4.5e-06	3.74e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—IL6—obesity	4.46e-06	3.71e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—MAPK8—obesity	4.42e-06	3.67e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—AKT1—obesity	4.4e-06	3.66e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—PIK3CA—obesity	4.4e-06	3.66e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—TYK2—obesity	4.37e-06	3.64e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—RHOA—obesity	4.34e-06	3.61e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PIK3R1—obesity	4.29e-06	3.57e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—NOS3—obesity	4.29e-06	3.57e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—MTOR—obesity	4.27e-06	3.54e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PIK3CB—obesity	4.27e-06	3.54e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—MMP9—obesity	4.24e-06	3.52e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—MAPK8—obesity	4.12e-06	3.43e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—AKT1—obesity	4.11e-06	3.42e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—PIK3CA—obesity	4.09e-06	3.4e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—STAT3—obesity	4.04e-06	3.35e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PIK3CB—obesity	3.96e-06	3.29e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—MTOR—obesity	3.96e-06	3.29e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—AKT1—obesity	3.96e-06	3.29e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—IL6—obesity	3.9e-06	3.24e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—STAT3—obesity	3.77e-06	3.13e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—MYC—obesity	3.75e-06	3.12e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—TGFB1—obesity	3.74e-06	3.11e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—MMP9—obesity	3.71e-06	3.08e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—AKT1—obesity	3.68e-06	3.06e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—IL6—obesity	3.62e-06	3.01e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—MAPK8—obesity	3.61e-06	3e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—AKT1—obesity	3.6e-06	2.99e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—PIK3CA—obesity	3.56e-06	2.96e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—MYC—obesity	3.5e-06	2.91e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—TGFB1—obesity	3.5e-06	2.9e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—MMP9—obesity	3.44e-06	2.86e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—MAPK8—obesity	3.35e-06	2.78e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—AKT1—obesity	3.34e-06	2.78e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—STAT3—obesity	3.3e-06	2.74e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PIK3CA—obesity	3.18e-06	2.65e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—MYC—obesity	3.06e-06	2.55e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—STAT3—obesity	3.06e-06	2.55e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—TGFB1—obesity	3.06e-06	2.54e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PIK3CA—obesity	2.97e-06	2.47e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—AKT1—obesity	2.91e-06	2.41e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PIK3CA—obesity	2.89e-06	2.4e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—MYC—obesity	2.85e-06	2.37e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—TGFB1—obesity	2.84e-06	2.36e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—IL6—obesity	2.82e-06	2.34e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—IL6—obesity	2.63e-06	2.19e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—AKT1—obesity	2.6e-06	2.16e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PIK3CA—obesity	2.6e-06	2.16e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—AKT1—obesity	2.43e-06	2.02e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PIK3CA—obesity	2.42e-06	2.01e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—AKT1—obesity	2.36e-06	1.96e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—IL6—obesity	2.3e-06	1.91e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—IL6—obesity	2.14e-06	1.78e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—AKT1—obesity	2.12e-06	1.77e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—AKT1—obesity	1.97e-06	1.64e-05	CbGpPWpGaD
